Yan Xuebing, Yan Leilei, Zhou Jia, Liu Sihong, Shan Zezhi, Jiang Chunyu, Tian Yuan, Jin Zhiming
Department of General Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University 600, Yi-Shan Road, Shanghai 200233, China.
Department of Medicine, Soochow University 1, Shi-Zi Road, Suzhou 215006, China.
Int J Clin Exp Pathol. 2014 Dec 1;7(12):8715-23. eCollection 2014.
Colorectal cancer (CRC) is one of the most common and fatal malignancies worldwide. Novel prognostic biomarkers are urgently warranted to help improve the treatment of CRC. Y-box-binding protein 1 (YB-1) has been identified as a multifunctional oncoprotein in various malignancies. Our previous study has suggested that YB-1 may promote malignant progression of CRC cells in vitro. However, its clinical and prognostic significance in CRC patients remains unclear. In this study, the expression of YB-1 was examined in 32 fresh CRC tissues using quantitative real-time polymerase chain reaction (qRT-PCR) and in 170 paraffin-embedded CRC tissues using immunohistochemistry. The result of qRT-PCR demonstrated mRNA expression of YB-1 was increased in 26 of 32 (81.25%) of CRC patients. The statistical analysis based on immunohistochemical staining suggested that YB-1 expression was significantly correlated with tumor differentiation, tumor invasion, lymph node metastasis and Dukes' classification (all P<0.05). Furthermore, we found that patients with high YB-1 expression had a poorer prognosis and were more likely to undergo local recurrence, compared to those with low YB-1 expression. We also identified that YB-1 expression, together with lymph node metastasis and Dukes' classification were independent prognostic factors for CRC patients. In conclusion, our study for the first time demonstrated the clinical and prognostic significance of YB-1 in CRC and suggested that YB-1 is of great potential to be an attractive therapeutic target as well as prognostic biomarker for CRC patients.
结直肠癌（CRC）是全球最常见且致命的恶性肿瘤之一。迫切需要新的预后生物标志物来帮助改善CRC的治疗。Y盒结合蛋白1（YB-1）已被确定为多种恶性肿瘤中的一种多功能癌蛋白。我们之前的研究表明，YB-1可能在体外促进CRC细胞的恶性进展。然而，其在CRC患者中的临床和预后意义仍不清楚。在本研究中，使用定量实时聚合酶链反应（qRT-PCR）检测了32例新鲜CRC组织中YB-1的表达，并使用免疫组织化学检测了170例石蜡包埋CRC组织中YB-1的表达。qRT-PCR结果显示，32例CRC患者中有26例（81.25%）的YB-1 mRNA表达增加。基于免疫组织化学染色的统计分析表明，YB-1表达与肿瘤分化、肿瘤侵袭、淋巴结转移和Dukes分期显著相关（均P<0.05）。此外，我们发现，与低YB-1表达的患者相比，高YB-1表达的患者预后较差，更易发生局部复发。我们还确定，YB-1表达与淋巴结转移和Dukes分期是CRC患者的独立预后因素。总之，我们的研究首次证明了YB-1在CRC中的临床和预后意义，并表明YB-1作为CRC患者有吸引力的治疗靶点和预后生物标志物具有巨大潜力。
